Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma

Poolbeg Pharma Plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, has announced that CEO, Jeremy Skillington, will be participating in the following leading industry conferences in March and April 2025:

Master Investor Show – Business Design Centre, London, UK

Presentation details: 29 March, Showcase Stage (Ground Floor), 1.00pm – 1.10pm

Poolbeg Pharma will be located at Booth M30.

BioTrinity – Convene, 133 Houndsditch, London, UK

Presentation details: 2 April, Science Spotlight 8 – Rare Disease, 9.30am – 11am

Poolbeg Pharma’s presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.

LSX World Congress – Business Design Centre, London, UK

Panel title: “Thriving Amidst Turbulence: Building Resilience in Life Sciences”

Panel date & time: 30 April, 2pm

If you would like to meet the Poolbeg Pharma team at any of the above events, please contact us at [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.
HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.
HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity.

Search

Search